Luoda is developing a formulation for pain relief in cats with significant potential for products with enhanced efficacy, safety and convenience as compared to existing treatments.
Pain relief in cats.
| Development Status: | Clinical Development Ongoing |
| Licence Status: | Pharma company partner being sought |
| Commercialisation Date: | Estimated 2019 |
Luoda has developed a combination product with antibacterial, antifungal and anti-inflammatory activity which is administered as a single long acting application into the canine external ear canal under light sedation by a veterinarian. This eliminates the need for application to the ear 2-3 times a day, increasing the likelihood of therapeutic success in this notoriously difficult to treat condition.
Otitis externa (infection of the external ear canal) in dogs
| Development Status: | Clinical Development Ongoing |
| Licence Status: | Pharma company partner being sought |
| Commercialisation Date: | Estimated 2019 |
Luoda is developing a unique oral liquid combination product to improve compliance and effectiveness.
Congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation) in dogs.
| Development Status: | Clinical Development Ongoing |
| Licence Status: | First stage funding obtained |
| Commercialisation Date: | Estimated 2019 |
Luoda is developing long acting product which is injected weekly to treat equine gastric ulcers.
Gastric ulcers are a major affliction of horses, particular race horses. Some recent studies have suggested that there are shortcomings with the commercially available products in terms of, not only administrative ease and compliance, but also efficacy.
| Development Status: | Clinical Development Ongoing |
| Licence Status: | Pharma company partner being sought |
| Commercialisation Date: | Estimated 2020 |
Luoda has developed a mastitis challenge model of Streptococcus uberis, one of the most common causes of mastitis worldwide, with the goal of assessing the safety, efficacy and milk withholding period of a novel intramammary product. Luoda has already tested one of its lead compounds against Streptococcus uberis in cattle and has demonstrated effectiveness equivalent to a leading commercial product currently available. A challenge model of Staphylococcus aureus mastitis has also been developed.
Bovine mastitis is most commonly caused by bacterial infection of the cow’s udder which reduces milk production and is potentially fatal.
| Development Status: | Clinical Development Ongoing |
| Licence Status: | First stage funding obtained |
| Commercialisation Date: | Estimated 2020 |
Luoda has invented, patented, developed, registered and manufactured a novel oral liquid formulation of pimobendan to improve ease and reliability of administration, compliance and effectiveness.
Congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation) in dogs.
| Development Status: | Registration submitted |
| Licence Status: | Partner / funding secured |
| Commercialisation Date: | November 2016 |
